source
- Merck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trialMerck & Co.’s sacituzumab tirumotecan has improved overall survival in a phase 3 cancer trial, delivering a second pivotal global victory for the TROP2-directed antibody-drug conjugate.
- Heraeus Medevio issues recall of vascular guidewires over coating safety riskThe FDA's Center for Devices and Radiological Health has posted an Early Alert warning about a potentially high‑risk issue with certain vascular guidewires. The alert notes that the coating on the…